Abstract
AbstractPurpose: Retinal pigment epithelial (RPE) cells in patients with age‐related macular degeneration are presumably senescent. This study investigated the effects of ranibizumab and bevacizumab on the viability of senescent RPE cells.Methods: Premature senescence of human RPE (ARPE‐19) cells was induced by exposure to low‐dose pulsed H2O2 stress for 5 days and confirmed with senescence‐associated 𝛽‐galactosidase (SA‐𝛽‐gal) staining. After treatment with clinical doses of ranibizumab and bevacizumab, the MTT [3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐Diphenyltetrazolium Bromide] assay and flow cytometry were used to determine cell viability. A caspase 3/7 assay, cell cycle analysis, SA‐𝛽‐gal staining, and in vitro wound healing assay were also performed to investigate the effects of the drugs on senescent ARPE‐19 cells.Results: Ranibizumab and bevacizumab did not have deleterious effects on apoptosis, cell viability, additional senescence, or the migration capacity of senescent RPE cells.Conclusions: Clinical dosages of ranibizumab and bevacizumab do not produce significant cytotoxicity in senescent RPE cells.Reference1. Klein R, Klein BE, Jensen SC, Meuer SM. The five‐year incidence and progression of age‐related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997; 104: 7–21.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
